Henlius is lined up to copy 4 of the blockbuster drugs on this tracker, which earned $52.5B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Henlius's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Prolia Bildyos |
Amgen | Biosimilar | 2025 | FDA-approved biosimilar | $4.4B |
| Xgeva Bilprevda |
Amgen | Biosimilar | 2025 | FDA-approved biosimilar | $2.1B |
| Keytruda | Merck | Biosimilar | 2028 | In clinical trials | $31.7B |
| Darzalex HLX15 |
Johnson & Johnson | Biosimilar | 2029 | Phase 1; first patient dosed May 2026 | $14.3B |
Company facts: Yahoo Finance. Each drug page lists sources for these entries. Brand sales show the size of the market, not Henlius's share of it.